Fulcrum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-97.34	-109.87	-80.85	-70.82	-89.81	-39.15	-25.37
Depreciation & Amortization	2.17	2.41	2.52	2.38	2.05	1.35	0.72
Share-Based Compensation	14.8	13.35	11.07	7.35	4.22	2.16	1.37
Other Operating Activities	-10.6	-2.94	-11.22	7.44	36.92	6.52	0.8
Operating Cash Flow	-90.97	-97.05	-78.48	-53.66	-39.48	-22.56	-20.07
Capital Expenditures	-0.51	-1.96	-1.71	-1.34	-0.85	-8.98	-1.91
Acquisitions	0	0	0	0	-0.09	0	0
Change in Investments	-36.18	14.38	-127.96	-55.8	0	0	0
Investing Cash Flow	-36.69	12.41	-129.67	-57.14	-0.94	-8.98	-1.91
Share Issuance / Repurchase	118.12	84.32	186.53	71.18	64.42	0.01	0.04
Debt Issued / Paid	0	0	-0.02	-0.05	-0.05	-0.07	0
Other Financing Activities	-	-	-	-	-0.03	105.08	17.62
Financing Cash Flow	118.12	84.32	186.51	71.13	64.34	105.03	17.66
Net Cash Flow	-9.54	-0.31	-21.64	-39.66	23.92	73.48	-4.32
Free Cash Flow	-91.47	-99.01	-80.19	-55	-40.34	-31.54	-21.98
Free Cash Flow Margin	-3261.07%	-1561.23%	-418.47%	-623.34%	-	-	-
Free Cash Flow Per Share	-1.49	-2.20	-2.27	-2.17	-3.65	-25.09	-30.92

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).